When small degrees of bias in randomized trials can mislead clinical decisions: An example of individualizing preventive treatment of upper gastrointestinal bleeding

Critical Care Medicine

Volumn 30, Issue 7, 2002, Pages 1503-1507

  Kunz, Regina ^a   Neumayer, Hans Hellmut ^a   Khan, Khalid S ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Bias; Clinical trials; Decision making; Double blind method; Gastrointestinal hemorrhage; Histamine H2 antagonists; Random allocation; Risk factors; Treatment outcome

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DIGESTIVE SYSTEM HEMORRHAGE; HUMAN; MEDICAL DECISION MAKING; META ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS;

EID: 0036313567     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200207000-00018     Document Type: Article

References (14)

1. Randomized trials or observational tribulations?
2. Which clinical studies provide the best evidence? The best RCT still trumps the best observational study
3. Guidelines for managing raised blood pressure
4. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
5. The unpredictability paradox: Review of empirical comparisons of randomised and non-randomised clinical trials
6. Improving the quality of reporting of randomized controlled trials. The CONSORT statement
7. Who benefits from medical interventions?
8. Users' guides to the medical literature. IX. A method for grading health care recommendations
9. The number needed to treat: A clinically useful measure of treatment effect
10. An assessment of clinically useful measures of the consequences of treatment
11. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses
12. Risk factors for gastrointestinal bleeding in critically ill patients
13. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
14. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women